^
    Back
    Association details:
    Biomarker:H3.3K27M
    Cancer:Glioma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    dordaviprone (ONC201) (AKT inhibitor, ERK inhibitor, DRD2 antagonist, ClpP agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2020
    Title:

    Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma

    Excerpt:
    Treatment with ONC201 alone or combined with bevacizumab is well tolerated in patients with recurrent H3 K27M-mutant scDG and a subset of patients experiences prolonged survival that exceeds historical outcomes.
    DOI:
    10.1200/JCO.2020.38